

Navinci to Showcase Omni at EACR 2026

Uppsala, Sweden – June 5, 2026 — Navinci, a leader in spatial interactomics solutions, today announces its participation in the European Association for Cancer Research (EACR) 2026 Congress, taking place from June 8–11, 2026 in Budapest, Hungary.

At EACR 2026, Navinci will highlight its growing portfolio of *in situ* proximity ligation assay (isPLA) based technologies and introduce Omni, a new solution designed to expand the scope of spatial protein analysis.

Omni is a multiplex immunoassay platform built on Navinci's proprietary isPLA technology, enabling spatially resolved detection of protein–protein interactions, post-translational modifications, and single protein expression in human tissue samples.

Designed for research use, Omni allows scientists to investigate signaling pathways and biological processes with high specificity and sensitivity while preserving spatial context. The platform supports multiplex analysis, enabling researchers to study multiple targets simultaneously and gain deeper insight into molecular interactions and cellular heterogeneity.

Attendees are invited to connect with the Navinci team at booth 27 during the congress to learn more about Omni, explore applications of isPLA in cancer research, and discuss potential collaborations.

[Book a meeting with the team on site here.](#)

For further information, please contact:

Kjell Ruth, Chief Commercial Officer

E-mail: kjell.ruth@navinci.se

About Navinci

Navinci is a Swedish biotech company specializing in developing innovative solutions for studying *in situ* protein expression and interactions. With a focus and a strong legacy in developing *in situ* proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.